OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
US$Â 4.98
arrow_upward
+1.12%(+0.055) Siku 1
16 Okt, 16:00:00 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya OPHLY...
Fungua
US$Â 5.05
Juu
US$Â 5.07
Chini
US$Â 4.98
Mtaji wa soko
1.20T
Wastani wa kiasi cha mauzo
elfu 62.80
Kiasi cha mauzo ya hisa
elfu 20.91
Juu kwa wiki 52
US$Â 5.75
Chini kwa wiki 52
US$Â 3.82
Beta
0.21
Hisa za wawekezaji
1.50B
Idadi ya wafanyakazi
elfu 4
Fungua
US$Â 5.05
Juu
US$Â 5.07
Chini
US$Â 4.98
Mtaji wa soko
1.20T
Wastani wa kiasi cha mauzo
elfu 62.80
Kiasi cha mauzo ya hisa
elfu 20.91
Juu kwa wiki 52
US$Â 5.75
Chini kwa wiki 52
US$Â 3.82
Beta
0.21
Hisa za wawekezaji
1.50B
Idadi ya wafanyakazi
elfu 4
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Simply Wall Street
·
saa 3 zilizopita
Learn Why The Bull Case For Ono Pharmaceutical Stock Could Change Following Biohaven Licensing Deal
Wasifu
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Kuhusu Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
Afisa Mkuu Mtendaji (CEO)Gyo Sagara | Gyo Sagara
Wafanyakazielfu 4.21
Lilianzishwa1717
Makao makuuOsaka, Mkoa wa Osaka, Japani
Sekta-
Tovutiono-pharma.com